natgillin/translations-raw huggingface dataset:
In a further embodiment, the lipophilic active compound is a veterinary drug and the invention provides a veterinary composition comprising at least one lipophilic veterinary drug interwoven with a polymeric matrix formed by two or more polymers, wherein said polymeric matrix is not crosslinked and no covalent interaction occurs between the two or more polymers and between the polymers and the at least one lipophilic veterinary drug. In one embodiment, the veterinary composition comprises itraconazole and a polymer matrix formed by an amphiphilic polymer, preferably Poloxamer 407, and a hydrophilic polymer, preferably chitosan or NaCMC, or the polymer matrix is formed by two amphiphilic polymers, preferably PVP and corn zein. 
Kruti farmaceutski pripravak prema zahtjevu 1, koji sadrži dva lipofilna aktivna spoja, poželjno fenofibrat i atorvastatin, oba smještena u bliskom kontaktu s polimernom matricom, pri čemu navedena polimerna matrica nije poprečno povezana 1 ne dolazi do kovalentne interakcije između dva ili više polimera i između polimera i lipofilnih lijekova, navedena je matrica poželjno načinjena od dva polimera, jedan od polimera je amfifilni polimer, poželjno Poloksamer 407, a drugi polimer je hidrofilni polimer, poželjno natrijeva karboksimetilceluloza, natrijev alginat ili hitozan.
The method according to claim 1, wherein the composition comprises a pharmaceutically acceptable carrier and/or one or more excipients. 
Uporaba prema zahtjevu 1, naznačena time, da lijek sadrži farmaceutski prihvatljiv nosač i/ili jedno ili više pomoćnih sredstava.
The antibody of claim 3, wherein the antibody comprises a heavy chain comprising a heavy chain variable region consisting of amino acid sequence SEQ ID NO: 16 and a heavy chain constant region which is a human gamma-1 heavy chain constant region, and a light chain comprising a light chain variable region consisting of amino acid sequences SEQ ID NO: 19 and a light chain constant region which is a human kappa light chain constant region. 
Antitijelo prema zahtjevu 1, pri čemu antitijelo obuhvaća teški lanac koji obuhvaća varijabilno područje teškog lanca koji se sastoji iz sekvence aminokiselina koja je prikazana u SEQ ID NO: 16 i konstantno područje teškog lanca koji je konstantno područje humanog gama-1 teškog lanca, i laki lanac koji obuhvaća varijabilno područje lakog lanca koji se sastoji iz sekvenci aminokiselina koje su prikazane u SEQ ID NOS: 19 i konstantnog područja lakog lanca koji je konstantno područje humanog kapa lakog lanca.
A composition comprising ivermectin for use to control Dirofilaria immitis and/or Dirofilaria repens infestation in a dog, wherein said ivermectin composition is in the form of an implant, wherein said implant is administered at least once a year and delivers ivermectin under conditions allowing to maintain a concentration of 0.1 ng per mL of plasma during at least 6 months. 
Sastav koji sadrži ivermektin za uporabu u kontroli zaraze Dirofilaria immitis-om i/ili Dirofilaria repens-om u psu, pri čemu je navedeni pripravak ivermektina u obliku implanta, pri čemu se navedeni implant primjenjuje barem jednom godišnje 1 isporučuje ivermektin pod uvjetima koji omogućuju održavanje koncentracije od 0,1 ng po mL plazme tijekom barem 6 mjeseci.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
The insert 20 is therefore provided with an internal base 21 and an external base 22 with reference to its placement inside the stock. 
Umetak 20 je u tu svrhu snabdjeven s unutarnjom bazom 21 i s vanjskom bazom 22 koje su usklađene s njegovim položajem unutar kundaka.
Figure 10 illustrates the cross-sectional view of the blender container 106 . 
Slika 10 daje poprečni prikaz posude mješalice 106.
is thienyl or phenyl, said thienyl or phenyl substituted with 2 or 3 of the same or different halo atoms; and 
je tienil ili fenil, gdje je navedeni tienil ili fenil supstituiran s 2 ili 3 ista ili različita atoma halogena; i
Cy is selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; 
Cy se odabire od supstituiranog ili nesupstituiranog cikloalkila, supstituirane ili nesupstituirane heterocikličke skupine, supstituiranog ili nesupstituiranog arila i supstituiranog ili nesupstituiranog heteroarila;
The additive composition according to claim 1, wherein the cleaning/stain-removing component (i) consists of: 
gdje je pH kompozicije niži od 6; i gdje se komponenta (i) za čišćenje/uklanjanje mrlja sastoji od:
AMP useful in the present invention may comprise impurities such as secondary alkanol amines, e.g. 2-methyl-2(methylamino)-1-propanol in an amount of less than 6% by weight, preferably in an amount of from 2 to 5% by weight, relative to the total weight of the impure AMP. 
Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da navedeni AMP može biti nepročišćen AMP koji sadrži sekundarne alkanol amine kao što je 2-metil-2(metilamino)-1-propanol u količini od manje od 6% težinski, poželjno u količini od 2 do 5 % težinski, u odnosu na ukupnu težinu nepročišćenog AMP.
Significance criteria: ≥ 50% of maximum stimulation or inhibition Sigma σ 2 Receptor: 
Signifikantni kriterij: > 50% maksimalne stimulacije ili inhibicije (h) Sigma g, receptor:
Compound of formula (I) 
Spoj formule (I):
hydrolysis, in the presence of an enzymatic composition as claimed in claim 9, of the lignocellulosic biomass so as to produce a hydrolysate containing glucose; 
– hidrolize u prisutnosti enzimskog pripravka u skladu s patentnim zahtjevom 10 lignocelulozne biomase na takav način da se dobije hidrolizat koji sadrži glukozu;
The antibody or an antigen binding fragment thereof for the use of any one of the previous claims, wherein the antibody or antigen binding fragment thereof further comprises a human k light chain constant region. 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što protutijelo ili njegov ulomak koji veže antigen nadalje sadrži humanu x konstantnu regiju lakog lanca.
cleaving said cleavable peptide or protein from said fusion polypeptide to liberate said CNP variant. 
cijepanje navedenog cijepajućeg peptida ili bjelančevina iz navedenog fuzijskog polipeptida radi oslobađanja navedene CNP varijante.
Matrix materials prepared from hydrophobic materials, such as hydrophobic polymers, waxes, fats, long-chain fatty acids, fatty alcohols or corresponding esters or ethers or mixtures thereof are also preferred. 
Isto tako su pogodni materijali za matricu iz hidrofobnih materijala, kao što su hidrofobni polimeri, voskovi, masti, dugolančane masne kiseline, masni alkoholi ili odgovarajući esteri ili eteri ili njihove smjese.
A palatable liquid pharmaceutical formulation according to claim 1 comprising: about 50-200 grams of deferiprone per litre of the formulation, about 15 grams of sucralose per litre of the formulation, about 500 grams of glycerin per litre of the formulation, about 1 gram of hydroxyethylcellulose per litre of the formulation, about 59 grams of concentrated hydrochloric acid per litre of the formulation, about 0.40 grams of FD&C Yellow No. 
Ukusna tekuća farmaceutska formulacija prema zahtjevu 1 koja sadrži: oko 50-200 grama deferiprona po litri formulacije, oko 15 grama sukraloze po litri formulacije, oko 500 grama glicerina po litri formulacije, oko 1 gram hidroksietilceluloze po litri formulacije, oko 59 grama koncentrirane klorovodične kiseline po litri formulacije, oko 0.40 grama FD&C Yellow No.
the on and off switching elements of automatic control block (AC) represents an input remote intelligent peripheral (IP) that processes, in the form of its functional algorithms, the input signals, that are automatically invoked by the journey of a train to the input commands and transfer the status of these input commands through the backed-up data transfer (DT) to the backed-up programmable control block (CB), while 
- preklopni elementi za uključivanje 1 isključivanje bloka automatskog nadzora (AC) predstavljaju ulaznu daljinsku inteligentnu perifernu opremu (IP) koja obrađuje, u obliku njezinih funkcionalnih algoritama, ulazne signale, koji se automatski pozivaju putovanjem vlaka, u ulazne naredbe i prebacuje status navedenih ulaznih naredbi putem prijenosa pričuvnih podataka (DT) prema pričuvnom programibilnom upravljačkom bloku (CB), pri čemu
The liquefied gas treatment system according to claim 3, wherein the sub LNG supply line includes a gas-liquid separator configured to separate a heavy hydrocarbon component from the LNG so as to adjust a methane number of the fuel to a value necessary for the sub engine. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 3, naznačen time što pomoćna linija za slanje LNG (L24) sadrži separator plina od tekućine (46), podešen za razdvajanje teške ugljikovodične komponente od LNG, kako bi se podesilo metanski broj goriva do vrijednosti potrebne za pomoćni motor.
to give the compound of the formula (VIII) 
da se dobije spoj s formulom (VIII) F i
The antibody for use according to claim 3, in which the antibody is a monoclonal, chimeric or humanized antibody, or is a fragment of an antibody, said fragment specifically binding to the tumor-associated antigen according to claim 3. 
Farmaceutski pripravak radi primjene sukladno bilo kojem od zahtjeva 1 do 3, pri čemu je protutijelo monoklonalno, kimerno ili humanizirano protutijelo ili fragment koji veže antigen protutijela.
Y represents two hydrogen atoms, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; and/or 
Y predstavlja dva atoma vodika, atom kisika ili C;.> alkilnu skupinu i atom vodika;
at least 24% of the cells in the population express on their surfaces detectable levels of CD99, 
(vi) najmanje 24 % stanica u populaciji na svojoj površini izražava uočljive razine CD99,
After blowing the container 2 into shape the container 2 is filled with the desired beverage and closed by pressing the base unit 3 over the neck, after removal of the upper seal. 
Kad se spremnik 2 napuhne u svoj oblik, spremnik 2 se puni sa željenim pićem i zatvara se tako da se osnovnu jedinicu 3 pritisne preko vrata, nakon odstranjivanja gornje brtve.
The binder according to claim 30, wherein the further hydraulically reactive material is Portland cement. The binder according to claim 32, wherein the not hydraulically reactive material is selected from the group consisting of ground limestone/dolomite, precipitated CaCO3, Ca(OH)2, Mg(OH)2, silica fume, and mixtures thereof. 
Vezivo sukladno barem jednom od zahtjeva 3 do 6, naznačeno time što dodatno sadrži hidraulički reaktivne materijale, poput Portland cementa i/ili ne hidraulički reaktivne materijale, poput mljevenog vapnenca/dolomita, istaloženog CaCO:s, Ca(OH) 2, Me(OH) 2, silikonskog dima raspona od 1 do 30 % mase, poželjno od 5 do 20 % mase.
The medication delivery device according to claim 1, characterised in that the adjusted medication dose AD is equal to the first dose if the variable B is negative and is equal to the second dose if the variable B is positive. 
Uređaj za izdavanje lijeka u skladu sa zahtjevom 1 naznačen time da je prilagođena doza lijekova AD jednaka prvoj dozi ako je varijabla B negativna i jednaka drugoj dozi ako je varijabla B pozitivna.
A process for preparing a formulation comprising a compound of formula I, or a salt thereof, as defined in claim 1, which process is characterised in that it includes a process for preparing a compound of formula I as claimed in any one of claims 1 to 3, followed by bringing into association the compound of formula I (or a salt thereof) so formed, with the ingredients that form a part of the formulation. 
HR P20180397 T1 IVb 13. Postupak za dobivanje formulacije koja sadrži spoj formule I, ili njegove soli, kao što se definirano u Zahtjevu 1, pri čemu je postupak naznačen time da obuhvaća postupak za dobivanje spoja formule I kako je navedeno u bilo kojem od zahtjeva 1 do 3, nakon čega slijedi povezivanje tako nastalog spoja I (ili njegove soli), sa sastojcima koji tvore formulaciju.
20, wherein binding affinity of the molecule for the activated form of the B chain is greater than binding affinity of the molecule for the B chain in zymogen form. The molecule of para. 
Molekula prema bilo kojem zahtjevu 19 do 23, naznačena time, da je afinitet vezanja molekule za aktivirani oblik lanca veći od afiniteta vezanja molekule za lanac u zimogenom obliku.
converting the product of step (d) to 
(6) prevođenju produkta iz koraka (d) u
A kit for treating a solid tumor in a human patient, the kit comprising: 
Set za primjenu u metodi za liječenje raka kod humanog pacijenta, set koji sadrži:
Use of a pharmaceutical composition as defined in at least one of the aspects 1-11 for the preparation of a medicament for treating at least one metabolic syndrome and/or atherosclerosis in a patient. 
Uporaba farmaceutskog pripravka kao što je definirano u barem jednom od zahtjeva 1-11 naznačena time što je za dobivanje lijeka za liječenje dijabetesa kod pacijenta.
Method according to claim 6, wherein the mixture comprises an acid in an amount of from 0.1 to 20 % by weight based on the amount of water. 
Postupak prema zahtjevu 6, naznačen time da smjesa sadrži kiselinu u količini od 0.1 do 20 % težinski temeljeno na količini vode.
The method of claim 15, wherein the cancer is cancer of the buccal cavity and pharynx, cancer of the digestive tract, cancer of the colon, rectum, and anus, cancer of the respiratory tract, breast cancer, cancer of the cervix uteri, vagina, and vulva, cancer of the uterine corpus and ovary, cancer of the male genital tract, cancer of the urinary tract, cancer of the bone and soft tissue, and Kaposi sarcoma, melanoma of the skin, eye melanoma, and non-melanoma eye cancer, cancer of the brain and central nervous system, cancer of the thyroid and other endocrine glands, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and myeloma, preferably renal cancer, colorectal cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, gastric cancer, GIST or glioblastoma. 
Farmaceutski sastav za uporabu prema zahtjevu 12, pri čemu je karcinom karcinom usne šupljine 1 ždrijela, karcinom probavnog trakta, karcinom debelog crijeva, rektuma i anusa, karcinom respiratornog trakta, karcinom dojke, karcinom grlića maternice, vagine i vulve, karcinom tijela maternice 1 jajnika, karcinom muškog genitalnog trakta, karcinom urinarnog trakta, karcinom kostiju i mekog tkiva, Kaposijev sarkom, melanom kože, melanom oka, nemelanomski karcinom oka, karcinom mozga i središnjeg živčanog sustava, karcinom žlijezde štitnjače i drugih endokrinih žlijezda, Hodgkinov limfom, ne-Hodgkinov limfom, ili mijelom kao što su karcinom bubrega, kolorektalni karcinom, karcinom pluća, karcinom dojke, karcinom gušterače, karcinom prostate, karcinom želuca, gastrointestinalni stromalni tumor (GIST) ili glioblastom.
The compound or mixture of compounds for use according to any one of claims 9-11, wherein the compound or mixture of compounds in the pharmaceutical composition is at a dosage of from 0.1 mg to 200 mg or from 10 mg to 100 mg. 
Spoj, ili smjesa spojeva, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 12 do 13, naznačen time što je spoj, ili smjesa spojeva, u obliku doziranja u dozi od 0,1 mg do 200 mg ili od 10 mg do 100 mg.
Said support 2 has a central opening 5 via which the laminated disc 1 can be mounted on a drive in a manner known as such. 
Nosač 2 ima središnji otvor 5 kroz koji može lamelirani disk 1 biti montiran na pogonski uređaj na način koji je kao takav poznat.
The liquefied gas treatment system according to claim 8, wherein the BOG, which is compressed by the compressor and is transferred to the heat exchanger, is compressed while passing through all or part of the plurality of compression cylinders included in the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 4, naznačen time što otpareni plin poslan u izmjenjivač topline (21) je otpareni plin komprimiran prilikom prolaska kroz sve ili dio kompresijskih elemenata koje sadrži kompresor (13,13,13b).
a group of formula -N2X, wherein X represents a suitable negatively-charged counterion (such as BF4-); or 
spoj formule -N>X, pri čemu X predstavlja pogodni negativno naelektrizirani suprotni ion (kao što je BF*");ili
In one embodiment, a flowable composition is provided further including a biocompatible polar aprotic organic liquid including N-methyl-2-pyrrolidone, 2-pyrrolidone, N,N-dimethylformamide, dimethyl sulfoxide, propylene carbonate, caprolactam, triacetin, or any combination thereof. 
Tekući pripravak prema zahtjevu 1, naznačen time da dodatno sadrži biokompatibilnu polarnu aprotičnu organsku tekućinu koja sadrži N-metil-2-pirolidon, 2-pirolidon, N,N-dimetilformamid, dimetil sulfoksid, propilen karbonat, kaprolaktam, triacetin, ili bilo koju njihovu kombinaciju.
At the same time, the beverage ingredient can be provided in different forms, such as e.g. 
Istodobno sastojak od kojeg sc pravi napitak može biti u različitim oblicima, poput npr.
desorbing said CO2 adsorbed on said solid sorbent (25) by heating said solid sorbent (25) so as to form a stream of desorbed CO2 (17') and a regenerated solid sorbent; cooling said regenerated solid sorbent. 
- < desorbiranju navedenog CO, adsorbiranog na navedeni čvrsti sorbent (25) grijanjem navedenog čvrstog sorbenta (25) kako bi se dobilo struju desorbiranog CO, (17') i regenerirani čvrsti sorbent;
Table 12 below shows a comparison of the binding affinities of Hc(G95M)Lc and HcLc. 
Svaki od dijagrama danih niže prikazuje reprezentativnu sliku iz tri neovisna ispitivanja. A nn nana
The DNA-targeting segment of a subject DNA-targeting RNA comprises a nucleotide sequence that is complementary to a sequence in a target DNA. 
(i) segment koji cilja na DNA, koji sadrži nukleotidni slijed komplementaran ciljanom slijedu u ciljanoj DNA, i
The present invention shall be illustrated by means of the following examples. 
Sljedeći će primjeri ilustrirati ovaj izum.
Use according to claim 1, wherein the biocompatible coating is a non-biodegradable coating selected from the group consisting of silica, alumina, sugar, phosphate, silane, switterionic compound, lipid, saturated carbon polymer and an inorganic polymer; or a biodegradable coating selected from the group consisting of biological polymer, phospholipid, saccharide, oligosaccharide and polysaccharide. 
Uporaba prema zahtjevu 1, gdje je biokompatibilna ovojnica ne-biorazgradiva ovojnica odabrana iz skupine koju čine silikon, aluminij, šećer, fosfat, silan, zwitter-ionski spoj, lipid, zasićeni ugljikov polimer 1 anorganski polimer; ili je biorazgradiva ovojnica odabrana iz skupine koju čine biološki polimer, fosfolipid, saharid, oligosaharid i polisaharid.
Its relative purity, determined by high performance liquid chromatography, is 90.2%. 
Njegova relativna čistpća, određena visokodjelotvornom tekućinskom kromatografijom, je 90,2 %.
The formulation of embodiment 816 or 817 in which the mature type I elastase protein is a human type I mature elastase protein. 
(c) formuliranje zrelog tipa I protein elastaze, na taj način proizvodeći farmaceutski sastav koji sadrži spomenuti zreli tip I protein elastaze.
A pharmaceutical composition, comprising a compound of claim 1, 14, 15, 16, 17, or 18 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time da sadržava Spoj iz zahtjeva 1, 14, 15, 16, 17, ili 18 i farmaceutski prihvatljivi nosač .
A host cell transformed with a vector of claim 10. The host cell of claim 11, wherein the host cell is derived from the group consisting of Saccharomyces, Schizosaccharomyces, Kluyveromyces, Pichia, Pichia, Hansenula, Aspergillus, Trichoderma, Penicillium, Candida and Yarrowina. 
stanica domaćina dobivena iz skupine koja se sastoji od pivskog kvasca, kvasca Schizosaccharomyces, kvasca Kluyveromyces, kvasca Pichia, kvasca Pichia, kvasca Hansenula, gljivica Aspergillus, gljivica Trichoderma, Kistaca, gljiva Chrysosporium, plijesni Chaetomium, plijesni Acremonium i kvasnice Candida i Yarrowina, i/ili
The obtained solid was washed with ether and then collected by filtration to obtain 2-fluoro-3-{2-[(1-propionylpiperidin-4-yl)methoxy]pyrimidin-5-yl}benzyl carbamimidoylcarbamate dihydrochloride (140 mg) as a colorless solid. 
Spoj ili njegova sol prema zahtjevu 1, naznačen/a time, da navedeni spoj je 3-(2-[(1-acetilpiperidin-4-il)metoksi|pirimidin-5-1l1)-2-fluorobenzil-karbamimidoilkarbamat, ili njegova sol.
The use according to claim 13, in which said cancer is selected from the group consisting of cancer of the breast, bladder, bone, brain, central and peripheral nervous system, colon, endocrine glands, esophagus, endometrium, germ cells, head and neck, kidney, liver, lung, larynx and hypopharynx, mesothelioma, sarcoma, ovary, pancreas, prostate, rectum, renal, small intestine, soft tissue, testis, stomach, skin, ureter, vagina and vulva; inherited cancers, retinomblastoma and Wilms tumor; leukemia, lymphoma, non-Hodgkins disease, chronic and acute myeloid leukaemia, acute lymphoblastic leukemia, Hodgkins disease, multiple myeloma and T-cell lymphoma; myelodysplastic syndrome, plasma cell neoplasia, paraneoplastic syndromes, cancers of unknown primary site and AIDS related malignancies. 
Upotreba u skladu s patentnim zahtjevom 13, naznačena time što se navedeni rak bira iz skupine koju čine rak dojke, mokraćnog mjehura, kostiju, mozga, središnjeg i perifernog živčanog sustava, debelog crijeva, endokrinih žlijezda, jednjaka, endometrija, germinativnih stanica, glave i vrata, bubrega, jetre, pluća, larinksa i hipofarinksa, mezoteliom, sarkom, rak jajnika, gušterače, prostate, rektuma, bubrežnog tkiva, tankog crijeva, mekog ikiva, testisa, želuca, kože, mokraćovoda, vagine i vulve; nasljedni oblici raka, retinomblastom i Wilmsov tumor; leukemija, limfom, nehodgkinovska bolest, kronična i akutna mijeloidna leukemija, akutna limfoblastična leukemija, Hodgkinova bolest, multipli mijelom i limfom T-stanica; mijelodisplastični sindrom, plazmacitne novotvorine, paraneoplastični sindromi, rak nepoznatog primarnog sijela i malignomi vezani uz AIDS.
Aa1 is a bisaryl radical made up of two aryl groups, which are selected independently from a group consisting of phenyl and naphthyl, and which are linked together via a single bond, 
Aal je bisarilni radikal, kojeg čine dvije arilne skupine, koje se neovisno bira iz skupine koju čine fenil i naftil, i zajedno su vezane jednostrukom vezom,
The target-binding moiety toxin conjugate of claim 6, wherein the amatoxin is an analog of a-amanitin, B-amanitin, Y-amanitin, e-amanitin, amanin, amaninamide, amanullin, or amanullinic acid containing a non-hydroxylated amino acid instead of a hydroxylated amino acid. 
Konjugat za ciljno vezanje djela toksina prema zahtjevu 6, naznačen time što je amatoksin analog a-amanitina, B-amanitina, Y-amanitina, e-amanitina, amanina, amaninamida, amanulina ili amanulinske kiseline koji sadrži ne-hidroksiliranu aminokiselinu umjesto hidroksilirane aminokiseline.
To further illustrate without limiting the invention an embodiment of R5 is hydrogen; another embodiment of R5 is C1-6-alkyl, such as methyl; a further embodiment of R5 is halogen, such as chloro, or fluoro. In a further embodiment of the compound of formula I, R6 is selected from hydrogen, halogen, C1-6-alk(en/yn)yl, halo-C1-6-alk(en/yn)yl. 
Za daljnju ilustraciju bez ograničenja ovog izuma jedna verzija R? je vodik; druga verzija R" je C,4-alkil poput metila; daljnja verzija R* je halogen poput klora ili fluora. U daljnjoj verziji spoja formule I, R* je odabran iz vodika, halogena, C;4-alk(en/in)ila, halo-C, -alk(en/in)ila.